Literature DB >> 19911999

Molecular and clinical assessment in the treatment of AIDS Kaposi sarcoma with valproic Acid.

Maryjo Lechowicz1, Dirk P Dittmer, Jeannette Y Lee, Susan E Krown, William Wachsman, David Aboulafia, Bruce J Dezube, Lee Ratner, Jonathan Said, Richard F Ambinder.   

Abstract

The AIDS Malignancy Consortium undertook a pilot trial of valproic acid among patients with AIDS-associated Kaposi sarcoma (KS). Treatment was associated with low toxicity, but the KS clinical response and KS herpesvirus lytic induction rates were not sufficiently high to meet predefined criteria for efficacy.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19911999      PMCID： PMC2952388          DOI： 10.1086/648447

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


  12 in total

1.  Valproic acid induces human herpesvirus 8 lytic gene expression in BCBL-1 cells.

Authors:  R N Shaw; J L Arbiser; M K Offermann
Journal:  AIDS       Date:  2000-05-05       Impact factor: 4.177

2.  Multiple mitochondrial DNA deletions and lactic acidosis in an HIV-infected patient under antiretroviral therapy.

Authors:  U A Walker; N Venhoff
Journal:  AIDS       Date:  2001-07-27       Impact factor: 4.177

3.  Transcription profile of Kaposi's sarcoma-associated herpesvirus in primary Kaposi's sarcoma lesions as determined by real-time PCR arrays.

Authors:  Dirk P Dittmer
Journal:  Cancer Res       Date:  2003-05-01       Impact factor: 12.701

4.  HIV-associated Kaposi's sarcoma with a high CD4 count and a low viral load.

Authors:  Toby Maurer; Maya Ponte; Kieron Leslie
Journal:  N Engl J Med       Date:  2007-09-27       Impact factor: 91.245

5.  More on HIV-associated Kaposi's sarcoma.

Authors:  Susan E Krown; Jeannette Y Lee; Dirk P Dittmer
Journal:  N Engl J Med       Date:  2008-01-31       Impact factor: 91.245

6.  Depletion of latent HIV-1 infection in vivo: a proof-of-concept study.

Authors:  Ginger Lehrman; Ian B Hogue; Sarah Palmer; Cheryl Jennings; Celsa A Spina; Ann Wiegand; Alan L Landay; Robert W Coombs; Douglas D Richman; John W Mellors; John M Coffin; Ronald J Bosch; David M Margolis
Journal:  Lancet       Date:  2005 Aug 13-19       Impact factor: 79.321

7.  Selective switch between latency and lytic replication of Kaposi's sarcoma herpesvirus and Epstein-Barr virus in dually infected body cavity lymphoma cells.

Authors:  G Miller; L Heston; E Grogan; L Gradoville; M Rigsby; R Sun; D Shedd; V M Kushnaryov; S Grossberg; Y Chang
Journal:  J Virol       Date:  1997-01       Impact factor: 5.103

8.  Stability of the latent reservoir for HIV-1 in patients receiving valproic acid.

Authors:  Janet D Siliciano; Jun Lai; Marc Callender; Eleanor Pitt; Hao Zhang; Joseph B Margolick; Joel E Gallant; Joseph Cofrancesco; Richard D Moore; Stephen J Gange; Robert F Siliciano
Journal:  J Infect Dis       Date:  2007-01-30       Impact factor: 5.226

9.  Matrix metalloproteinase inhibitor COL-3 in the treatment of AIDS-related Kaposi's sarcoma: a phase I AIDS malignancy consortium study.

Authors:  Mary Cianfrocca; Timothy P Cooley; Jeannette Y Lee; Michelle A Rudek; David T Scadden; Lee Ratner; James M Pluda; William D Figg; Susan E Krown; Bruce J Dezube
Journal:  J Clin Oncol       Date:  2002-01-01       Impact factor: 44.544

Review 10.  Valproate: past, present, and future.

Authors:  Cecilie U Johannessen; Svein I Johannessen
Journal:  CNS Drug Rev       Date:  2003
View more
  12 in total

Review 1.  Kaposi sarcoma-associated herpesvirus: immunobiology, oncogenesis, and therapy.

Authors:  Dirk P Dittmer; Blossom Damania
Journal:  J Clin Invest       Date:  2016-09-01       Impact factor: 14.808

2.  Oncolytic Reactivation of KSHV as a Therapeutic Approach for Primary Effusion Lymphoma.

Authors:  Feng Zhou; Michiko Shimoda; Laura Olney; Yuanzhi Lyu; Khiem Tran; Guochun Jiang; Kazushi Nakano; Ryan R Davis; Clifford G Tepper; Emanual Maverakis; Mel Campbell; Yuanpei Li; Satya Dandekar; Yoshihiro Izumiya
Journal:  Mol Cancer Ther       Date:  2017-08-28       Impact factor: 6.261

3.  Valproic acid antagonizes the capacity of other histone deacetylase inhibitors to activate the Epstein-barr virus lytic cycle.

Authors:  Derek Daigle; Lyn Gradoville; David Tuck; Vince Schulz; Ruth Wang'ondu; Jianjiang Ye; Kelly Gorres; George Miller
Journal:  J Virol       Date:  2011-03-16       Impact factor: 5.103

Review 4.  Bortezomib-induced Epstein-Barr virus and Kaposi sarcoma herpesvirus lytic gene expression: oncolytic strategies.

Authors:  Erin G Reid
Journal:  Curr Opin Oncol       Date:  2011-09       Impact factor: 3.645

5.  Activation and repression of Epstein-Barr Virus and Kaposi's sarcoma-associated herpesvirus lytic cycles by short- and medium-chain fatty acids.

Authors:  Kelly L Gorres; Derek Daigle; Sudharshan Mohanram; George Miller
Journal:  J Virol       Date:  2014-05-07       Impact factor: 5.103

6.  Update on HHV-8-Associated Malignancies.

Authors:  Meena Sunil; Erin Reid; Mary Jo Lechowicz
Journal:  Curr Infect Dis Rep       Date:  2010-03-26       Impact factor: 3.725

Review 7.  Molecular and therapeutic potential and toxicity of valproic acid.

Authors:  Sébastien Chateauvieux; Franck Morceau; Mario Dicato; Marc Diederich
Journal:  J Biomed Biotechnol       Date:  2010-07-29

8.  Targeting sphingosine kinase induces apoptosis and tumor regression for KSHV-associated primary effusion lymphoma.

Authors:  Zhiqiang Qin; Lu Dai; Jimena Trillo-Tinoco; Can Senkal; Wenxue Wang; Tom Reske; Karlie Bonstaff; Luis Del Valle; Paulo Rodriguez; Erik Flemington; Christina Voelkel-Johnson; Charles D Smith; Besim Ogretmen; Chris Parsons
Journal:  Mol Cancer Ther       Date:  2013-10-18       Impact factor: 6.261

9.  Pilot Trial AMC-063: Safety and Efficacy of Bortezomib in AIDS-associated Kaposi Sarcoma.

Authors:  Erin G Reid; Adrienne Suazo; Shelly Y Lensing; Dirk P Dittmer; Richard F Ambinder; Frank Maldarelli; Robert J Gorelick; David Aboulafia; Ronald Mitsuyasu; Mark A Dickson; William Wachsman
Journal:  Clin Cancer Res       Date:  2019-10-17       Impact factor: 12.531

10.  Restricted Kaposi's sarcoma (KS) herpesvirus transcription in KS lesions from patients on successful antiretroviral therapy.

Authors:  Dirk P Dittmer
Journal:  MBio       Date:  2011-11-01       Impact factor: 7.867
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.